U.S. patent application number 09/896296 was filed with the patent office on 2002-01-31 for gamma secretase inhibitors.
Invention is credited to Teall, Martin Richard.
Application Number | 20020013315 09/896296 |
Document ID | / |
Family ID | 9895191 |
Filed Date | 2002-01-31 |
United States Patent
Application |
20020013315 |
Kind Code |
A1 |
Teall, Martin Richard |
January 31, 2002 |
Gamma secretase inhibitors
Abstract
The invention provides compounds of formula (I) and
pharmaceutically acceptable salts thereof: 1 wherein X is CH.sub.2,
O or S. The compounds inhibit gamma secretase without affecting
Notch signalling, and hence find use in the treatment or prevention
of Alzheimer's disease.
Inventors: |
Teall, Martin Richard;
(Bishops Stortford, GB) |
Correspondence
Address: |
MERCK AND CO INC
P O BOX 2000
RAHWAY
NJ
070650907
|
Family ID: |
9895191 |
Appl. No.: |
09/896296 |
Filed: |
June 29, 2001 |
Current U.S.
Class: |
514/237.8 ;
514/227.5; 514/317; 544/168; 544/59; 546/234 |
Current CPC
Class: |
A61P 25/28 20180101;
A61K 38/00 20130101; C07K 5/06191 20130101; A61K 31/54 20130101;
A61K 31/5375 20130101; C07K 5/06026 20130101; A61K 31/451
20130101 |
Class at
Publication: |
514/237.8 ;
514/227.5; 514/317; 544/59; 544/168; 546/234 |
International
Class: |
A61K 031/54; A61K
031/5375; A61K 031/445; C07D 279/12; C07D 265/30; C07D 211/32 |
Foreign Application Data
Date |
Code |
Application Number |
Jul 6, 2000 |
GB |
0016681.9 |
Claims
1. A compound of formula I or a pharmaceutically acceptable salt
thereof: 4wherein: X is CH.sub.2, oxygen or sulphur; and Ar is
phenyl optionally substituted by one, two or three substituents
chosen from halogen, C.sub.1-6alkyl, C.sub.2-6alkenyl,
C.sub.2-6alkynyl, hydroxy, cyano, nitro, NR.sup.1R.sup.2 where
R.sup.1 and R.sup.2 are independently hydrogen or C.sub.1-6alkyl,
C.sub.1-6alkoxy, C.sub.2-6alkenyloxy, C.sub.2-6alkynyloxy, thiol,
C.sub.1-6alkylthio, C.sub.2-6alkenylthio, C.sub.2-6alkynylthio,
C.sub.1-6alkylcarbonyl, C.sub.1-6alkoxycarbonyl,
C.sub.1-6haloalkyl, C.sub.2-6haloalkenyl and
C.sub.2-6haloalkynyl:
2. A compound according to claim 1 wherein X is oxygen.
3. A compound according to claim 1 wherein Ar is optionally
substituted by one, two or three substituents chosen from halogen,
C.sub.1-6alkyl, hydroxy, amino, C.sub.1-6alkoxy, thiol,
C.sub.1-6alkoxycarbonyl and C.sub.1-6haloalkyl.
4. A compound according to claim 3 wherein Ar is optionally
substituted by one substituent chosen from halogen, C.sub.1-4alkyl,
hydroxy, amino, C.sub.1-4alkoxy, thiol, C.sub.1-4alkoxycarbonyl and
C.sub.1-4haloalkyl.
5. A compound according to claim 1 wherein Ar is unsubstituted.
6. A compound according to claim 1 selected from 2-[2-(3,5
-difluorophenyl)acetylamino]-N-{phenyl[(4-phenylmorpholin-2-ylmethyl)carb-
amoyl]methyl}propionamide and the pharmaceutically acceptable salts
thereof.
7. A pharmaceutical composition comprising one or more compounds
according to claim 1 and a pharmaceutically acceptable carrier.
8. A method of treatment of a subject suffering from or prone to
Alzheimer's disease which comprises administering to that subject
an effective amount of a compound according to claim 1.
9. A method of treatment according to claim 8 which does not
inhibit Notch signalling.
Description
[0001] The present invention relates to compounds, their salts,
pharmaceutical compositions comprising them, processes for making
them and their use in treating Alzheimer's Disease.
[0002] Alzheimer's Disease (AD) is characterized by the abnormal
deposition of amyloid in the brain in the form of extra-cellular
plaques and intra-cellular neurofibrillary tangles. The rate of
amyloid accumulation is a combination of the rates of formation,
aggregation and egress from the brain. It is generally accepted
that the main constituent of amyloid plaques is the 4 kD amyloid
protein (.beta.A4, also referred to as A.beta.,.beta.-protein and
.beta.AP) which is a proteolytic product of a precursor protein of
much larger size. The ragged NH.sub.2- and COOH-termini of the
native A.beta. amyloid indicates that a complex mechanism of
proteolysis is involved in its biogenesis.
[0003] The amyloid precursor protein (APP or A.beta.PP) has a
receptor-like structure with a large ectodomain, a membrane
spanning region and a short cytoplasmic tail. Different isoforms of
APP result from the alternative splicing of three exons in a single
gene and have 695,751 and 770 amino acids respectively.
[0004] The A.beta. domain encompasses parts of both extra-cellular
and transmembrane domains of APP, thus its release implies the
existence of two distinct proteolytic events to generate its
NH.sub.2- and COOH-termini. At least two secretory mechanisms exist
which release APP from the membrane and generate the soluble,
COOH-truncated forms of APP (APPs). Proteases which release APP and
its fragments from the membrane are termed "secretases". Most APPs
is released by a putative .alpha.-secretase which cleaves within
the A.beta.domain (between residues Lys.sup.16 and Leu.sup.17) to
release (.alpha.-APPs and precludes the release of intact A.beta..
A minor portion of APPs is released by a .beta.-secretase, which
cleaves near the NH.sub.2-terminus of A.beta. and produces
COOH-terminal fragments (CTFs) which contain the whole A.beta.
domain. Finding these fragments in the extracellular compartment
suggests that another proteolytic activity (.gamma.-secretase)
exists under normal conditions which can generate the COOH-terminus
of A.beta..
[0005] It is believed that .gamma. secretase itself depends for its
activity on the presence of presenilin-1. In a manner that is not
fully understood presenilin-1 appears to undergo autocleavage.
[0006] The potential of .gamma. secretase inhibitors to inhibit the
functioning of presinilins, which have been proposed as candidates
.gamma. secretases, has raised questions over their suitability. In
particular, signalling through the Notch pathway, important during
embryonic development and in haematopoeisis, requires the
presenilin-dependent proteolytic release of the Notch intracellular
domain (NICD). Using a novel Xenopus developmental assay for Notch
activity it has surprisingly been found that the present .gamma.
secretase inhibitors do not prevent Notch signalling in-vivo.
[0007] The present compounds are structurally related to those
disclosed in WO-A-9822494. However there is no discussion in that
document of the problem of interference of Notch signalling nor any
suggestion of how the provision of .gamma.-secretase inhibitors
that do not inhibit Notch signalling may be achieved.
[0008] Accordingly, the present invention provides a compound of
formula I or a pharmaceutically acceptable salt thereof: 2
[0009] wherein: X is CH.sub.2, oxygen or sulphur; and
[0010] Ar is phenyl optionally substituted by one, two or three
substituents chosen from halogen, C.sub.1-6alkyl, C.sub.2-6alkenyl,
C.sub.2-6alkynyl, hydroxy, cyano, nitro, NR.sup.1R.sup.2 where
R.sup.1 and R.sup.2 are independently hydrogen or C.sub.1-6alkyl,
C.sub.1-6alkoxy, C.sub.2-6alkenyloxy, C.sub.2-6alkynyloxy, thiol,
C.sub.1-6alkylthio, C.sub.2-6alkenylthio, C.sub.2-6alkynylthio,
C.sub.1-6alkylcarbonyl, C.sub.1-6alkoxycarbonyl,
C.sub.1-6haloalkyl, C.sub.2-6haloalkenyl and
C.sub.2-6haloalkynyl.
[0011] Preferably X is oxygen.
[0012] Preferably Ar is optionally substituted by one, two or three
substituents chosen from halogen, C.sub.1-6alkyl, hydroxy, amino,
C.sub.1-6alkoxy, thiol, C.sub.1-6alkoxycarbonyl and
C.sub.1-6haloalkyl.
[0013] More preferably Ar is optionally substituted by one
substituent chosen from halogen, C.sub.1-4alkyl, hydroxy, amino,
C.sub.1-4alkoxy, thiol, C.sub.1-4alkoxycarbonyl and
C.sub.1-4haloalkyl.
[0014] In one embodiment Ar is unsubstituted.
[0015] A specific Example of the present invention is:
2-[2-(3,5-difluorophenyl)acetylamino]-N-{phenyl[(4-phenylmorpholin-2-ylme-
thyl)carbamoyl]methyl}propionamide and the pharmaceutically
acceptable salts thereof.
[0016] As used herein, the expression "C.sub.1-6alkyl" includes
methyl and ethyl groups, and straight-chained and branched propyl,
butyl, pentyl and hexyl groups. Particular alkyl groups are methyl,
ethyl, n-propyl, isopropyl and t-butyl. Derived expressions such as
"C.sub.1-4alkyl", "C.sub.2-6alkenyl" and "C.sub.2-6alkynyl" are to
be construed in an analogous manner.
[0017] The term "halogen" as used herein includes fluorine,
chlorine, bromine and iodine, of which fluorine and chlorine are
preferred.
[0018] As used herein the term "C.sub.1-6alkoxy" includes methoxy
and ethoxy groups, and straight-chained, branched and cyclic
propoxy and butoxy groups, including cyclopropylmethoxy.
"C.sub.2-6alkynyloxy", "C.sub.2-6alkenyloxy", "C.sub.1-6alkylthio",
"C.sub.2-6alkenylthio", "C.sub.2-6alkynylthio" and
"C.sub.1-4alkoxy" are to be construed in analogous manner.
[0019] As used herein the term "C.sub.1-6alkoxycarbonyl" includes
methoxycarbonyl and alkoxycarbonyl groups and straight-chained,
branched and cyclic propoxycarbonyl and butoxycarbonyl groups,
including cyclopropylmethoxycarbonyl. "C.sub.1-4alkoxycarbonyl" is
to be construed in analogous manner.
[0020] Examples of pharmaceutically acceptable salts are
hydrochlorides, sulfates, citrates, tartrates, acetates,
methanesulfonates, phosphates, oxalates and benzoates.
[0021] The compounds of the present invention have an activity as
inhibitors of .gamma.secretase. In a preferred embodiment the
compounds of the invention inhibit proteolysis of PS-1.
[0022] The invention also provides pharmaceutical compositions
comprising one or more compounds of this invention and a
pharmaceutically acceptable carrier. Preferably these compositions
are in unit dosage forms such as tablets, pills, capsules, powders,
granules, sterile parenteral solutions or suspensions, metered
aerosol or liquid sprays, drops, ampoules, transdermal patches,
auto-injector devices or suppositories; for oral, parenteral,
intranasal, sublingual or rectal administration, or for
administration by inhalation or insufflation. For preparing solid
compositions such as tablets, the principal active ingredient is
mixed with a pharmaceutical carrier, e.g. conventional tableting
ingredients such as corn starch, lactose, sucrose, sorbitol, talc,
stearic acid, magnesium stearate, dicalcium phosphate or gums or
surfactants such as sorbitan monooleate, polyethylene glycel, and
other pharmaceutical diluents, e.g. water, to form a solid
preformulation composition containing a homogeneous mixture of a
compound of the present invention, or a pharmaceutically acceptable
salt thereof. When referring to these preformulation compositions
as homogeneous, it is meant that the active ingredient is dispersed
evenly throughout the composition so that the composition may be
readily subdivided into equally effective unit dosage forms such as
tablets, pills and capsules. This solid preformulation composition
is then subdivided into unit dosage forms of the type described
above containing from 0.1 to about 500 mg of the active ingredient
of the present invention. Typical unit dosage forms contain from 1
to 100 mg, for example 1, 2, 5, 10, 25, 50 or 100 mg, of the active
ingredient. The tablets or pills of the novel composition can be
coated or otherwise compounded to provide a dosage form affording
the advantage of prolonged action. For example, the tablet or pill
can comprise an inner dosage and an outer dosage component, the
latter being in the form of an envelope over the former. The two
components can be separated by an enteric layer which serves to
resist disintegration in the stomach and permits the inner
component to pass intact into the duodenum or to be delayed in
release. A variety of materials can be used for such enteric layers
or coatings, such materials including a number of polymeric acids
and mixtures of polymeric acids with such materials as shellac,
cetyl alcohol and cellulose acetate.
[0023] The present invention also provides a compound of the
invention or a pharmaceutically acceptable salt thereof for use in
a method of treatment of the human body. Preferably the treatment
is for a condition associated with the deposition of
.beta.-amyloid. Preferably the condition is a neurological disease
having associated .beta.-amyloid deposition such as Alzheimer's
disease. Preferably this treatment occurs without inhibiting Notch
signalling.
[0024] The present invention further provides the use of a compound
of the present invention or a pharmaceutically acceptable salt
thereof in the manufacture of a medicament for treating or
preventing Alzheimer's disease, preferably without inhibiting Notch
signalling.
[0025] Also disclosed is a method of treatment of a subject
suffering from or prone to Alzheimer's disease which comprises
administering to that subject an effective amount of a compound
according to the present invention or a pharmaceutically acceptable
salt thereof. This method of treatment preferably does not inhibit
Notch signalling.
[0026] The liquid forms in which the novel compositions of the
present invention may be incorporated for administration orally or
by injection include aqueous solutions, suitably flavored syrups,
aqueous or oil suspensions, and flavored emulsions with edible oils
such as cottonseed oil, sesame oil, coconut oil or peanut oil, as
well as elixirs and similar pharmaceutical vehicles. Suitable
dispersing or suspending agents for aqueous suspensions include
synthetic and natural gums such as tragacanth, acacia, alginate,
dextran, sodium carboxymethylcellulose, methylcellulose,
polyvinyl-pyrrolidone or gelatin.
[0027] For treating or preventing Alzheimer's Disease, a suitable
dosage level is about 0.01 to 250 mg/kg per day, preferably about
0.01 to 100 mg/kg per day, and especially about 0.01 to 5 mg/kg of
body weight per day. The compounds may be administered on a regimen
of 1 to 4 times per day. In some cases, however, dosage outside
these limits may be used.
[0028] There is also provided a process for producing a compound of
formula I or a pharmaceutically acceptable salt thereof which
comprises reacting a compound of formula II with a compound of
formula III: 3
[0029] wherein X and Ar are as defined above, generally in the
presence of a coupling agent such as
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide, and
hydroxybenzotriazole, generally in the presence of a base such as
triethylamine, and a solvent such as tetrahydrofuran, for about 18
h at room temperature.
[0030] Compounds of formulae II and III are commercially available
or can be made by known methods from commercially available
compounds.
[0031] It will be understood that any compound of formula I
initially obtained from the above process may, where appropriate,
subsequently be elaborated into a further compound of formula I by
techniques known from the art.
[0032] It will also be appreciated that where more than one isomer
can be obtained from a reaction then the resulting mixture of
isomers can be separated by conventional means.
[0033] Where the above-described process for the preparation of the
compounds according to the invention gives rise to mixtures of
stereoisomers, these isomers may be separated by conventional
techniques such as preparative chromatography. The novel compounds
may be prepared in racemic form, or individual enantiomers may be
prepared either by enantiospecific synthesis or by resolution.
[0034] During any of the above synthetic sequences it may be
necessary and/or desirable to protect sensitive or reactive groups
on any of the molecules concerned. This may be achieved by means of
conventional protecting groups, such as those described in
Protective Groups in Organic Chemistry, ed. J. F. W. McOmie, Plenum
Press, 1973; and T. W. Greene & P. G. M. Wuts, Protective
Groups in Organic Synthesis, John Wiley & Sons, 1991. The
protecting groups may be removed at a convenient subsequent stage
using methods known from the art.
[0035] A typical assay which can be used to determine the level of
activity of compounds of the present invention is as follows:
[0036] (1) Mouse neuroblastoma neuro 2a cells expressing human
app695 are cultured at 50-70% confluency in the presence of sterile
10 mM sodium butyrate.
[0037] (2) Cells are placed in 96-well plates at 30,000/well/100
.mu.L in minimal essential medium (MEM) (phenol red-free)+10%
foetal bovine serum (FBS), 5mM HEPES buffer (pH7.3), 1% glutamine,
0.2 mg/mL G418 antibiotic, 10 mM sodium butyrate.
[0038] (3) Make dilutions of the compound plate. Dilute stock
solution to 5.5% DMSO/110 .mu.M compound. Mix compounds vigorously
and store at 4.degree. C. until use.
[0039] (4) Add 10 .mu.L compound/well. Mix plate briefly, and leave
for 18 h in 37.degree. C. incubator.
[0040] (5) Remove 90 .mu.L of culture supernatant and dilute 1:1
with ice-cold 25mM HEPES (pH.3), 0.1% BSA, 1.0 mM EDTA (+broad
spectrum protease inhibitor cocktail; pre-aliquotted into a 96-well
plate). Mix and keep on ice or freeze at -80.degree. C.
[0041] (6) Add back 100 .mu.L of warm MEM +10% FBS, 50 mM HEPES
(pH7.3), 1% glutamine, 0.2 mg/mL G418, 10 mM sodium butyrate to
each well, and return plate to 37.degree. C. incubator.
[0042] (7) Prepare reagents necessary to determine amyloid peptide
levels, for example by ELISA assay
[0043] (8) To determine if compounds are cytotoxic cell viability
following compound administration is assessed by the use of redox
dye reduction. A typical example is a combination of redox dye MTS
(Promega) and the electron coupling reagent PES. This mixture is
made up according to the manufacturer's instructions and left at
room temperature.
[0044] (9) Quantitate amyloid beta 40 and 42 peptides using an
appropriate volume of diluted culture medium by standard ELISA
techniques.
[0045] (10) Add 15 .mu.L/well MTS/PES solution to the cells; mix
and leave at 37.degree. C.
[0046] (11) Read plate when the absorbance values are approximately
1.0 (mix briefly before reading to disperse the reduced formazan
product).
[0047] The Example of the present invention had an ED.sub.50 of
less than 500 nM in the above assay.
[0048] The following assay was used to determine the effect of
compounds on Notch signalling.
[0049] Xenopus embryos were cultured in {fraction (1/10)} NAM [Beck
& Slack, Development, 126, 1611-1620, 1999] supplemented with
protease inhibitors (200.times. stock in DMSO) from stage 15 [P. D.
Nieuwkoop and J. Faber, Normal table of Xenopus laevis, Daudin
1967, Reprinted Garland 1994] (24 hours), to stage 40 (3 days).
Control siblings were incubated in {fraction (1/10)} NAM containing
0.05% DMSO. At 3 days they were fixed in batches of 20 and measured
using a graduated eyepiece on a Wild dissecting microscope set to
25.times.. Each tadpole was measured from head to proctodaeum (head
and trunk) and from proctodaeum to tail tip (tail). Tail buds were
extirpated at stage 30 and cultured for 24 hours as described
previously [Tucker & Slack, Development, 121, 249-262, 1995].
Somites were detected by staining with monoclonal antibody 12/101
[Kintner & Brockes, Nature, 308, 67-69, 1984], as described
elsewhere [Tucker & Slack, 1995]. In situ hybridisation for
Xhox3 has been previously described [Beck & Slack, Mech. Dev.,
72, 41-52, 1998].
[0050] The Example of the present invention did not significantly
inhibit tail bud formation.
[0051] The following Examples illustrate the present invention.
EXAMPLE 1
[0052]
2-[2-(3,5-Difluorophenyl)acetylamino]-N-{phenyl[(4-phenylmorpholin--
2-ylmethyl)carbamoyl]methyl}propionamide
[0053] A mixture of
[(3,5-Difluorophenyl)acetylamino]-1-ethylcarbamoyl-1-p- henyl
ethanoic acid (20 mg, 0.053 mmol),
1-(3-dimethylaminopropyl)-3-ethyl carbodiimide (11.2 mg, 0.058
mmol) and hydroxybenzotriazole (7.8 mg, 0.058 mmol) in
tetrahydrofuran was treated with N-phenyl 2-aminomethyl morpholine
(15.2 mg, 0.079 mmol) and triethylamine (16 mg, 0.159 mmol) and the
reaction stirred for 18 hours at room temperature. Evaporation of
the solvent and purification on a bond elute cartridge gave the
product (6 mg). Mixture of diastereoisomers: (.sup.1H, DMSO)
8.45-8.34 (3 H, m), 7.43-6.76 (10 H, m), 5.44 (1 H, t), 4.44 (1 H,
t), 3.91 (1 H, br), 3.59-3.16 (11 H, m), 2.61 (1 H, dd), 2.26 (1
H,m), 1.22 (3 H, m) MS (CI+) MH+551.
* * * * *